Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.Common side effects include nasopharyngitis (cold), injection site reactions, and influenza.It was approved for medical use in the United States and in the European Union in 2015. Medical uses
Alirocumab is used as a second-line treatment to lower LDL cholesterol for adults who have a severe form of hereditary high cholesterol and people with atherosclerosis who require additional lowering of LDL cholesterol when diet and statin treatment have not worked. It is administered by subcutaneous injection. As of July 2015, it is not known whether alirocumab prevents early death from cardiovascular disease or prevents heart attacks; a clinical trial to determine outcomes was ongoing at that time, the results of which were expected in 2017. In November 2018, The New England Journal of Medicine published positive results from a clinical trial with alirocumab.
Claudes syndrome is a form of brainstem stroke syndrome characterized by the presence of an ipsilateral oculomotor nerve palsy, contralateral hemiparesis, contralateral ataxia, and contralateral hemiplegia of the lower face, tongue, and shoulder. Claudes syndrome affects oculomotor nerve, red nucleus and brachium conjunctivum. Cause
Claudes syndrome is caused by midbrain infarction as a result of occlusion of a branch of the posterior cerebral artery. This lesion is usually a unilateral infarction of the red nucleus and cerebellar peduncle, affecting several structures in the midbrain including:

It is very similar to Benedikts syndrome. Other causes
It has been reported that posterior cerebral artery stenosis can also precipitate Claudes syndrome. Diagnosis
History
It carries the name of Henri Charles Jules Claude, a French psychiatrist and neurologist, who described the condition in 1912. See also
Wallenbergs syndrome
Moritz Benedikt

References


== External links ==